- Home
- NUW vs ACIU Comparison
NUW vs ACIU Comparison
Compare NUW & ACIU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NUW
- ACIU
- Stock Information
- Founded
- NUW 2008
- ACIU 2003
- Country
- NUW United States
- ACIU Switzerland
- Employees
- NUW N/A
- ACIU N/A
- Industry
- NUW Investment Managers
- ACIU Biotechnology: Pharmaceutical Preparations
- Sector
- NUW Finance
- ACIU Health Care
- Exchange
- NUW Nasdaq
- ACIU Nasdaq
- Market Cap
- NUW 246.8M
- ACIU 213.3M
- IPO Year
- NUW N/A
- ACIU 2016
- Fundamental
- Price
- NUW $13.68
- ACIU $2.13
- Analyst Decision
- NUW
- ACIU Strong Buy
- Analyst Count
- NUW 0
- ACIU 1
- Target Price
- NUW N/A
- ACIU $12.00
- AVG Volume (30 Days)
- NUW 45.3K
- ACIU 160.7K
- Earning Date
- NUW 01-01-0001
- ACIU 08-05-2025
- Dividend Yield
- NUW 3.66%
- ACIU N/A
- EPS Growth
- NUW N/A
- ACIU N/A
- EPS
- NUW N/A
- ACIU N/A
- Revenue
- NUW N/A
- ACIU $36,362,036.00
- Revenue This Year
- NUW N/A
- ACIU N/A
- Revenue Next Year
- NUW N/A
- ACIU $533.21
- P/E Ratio
- NUW N/A
- ACIU N/A
- Revenue Growth
- NUW N/A
- ACIU 86.71
- 52 Week Low
- NUW $12.45
- ACIU $1.43
- 52 Week High
- NUW $14.44
- ACIU $3.98
- Technical
- Relative Strength Index (RSI)
- NUW 49.35
- ACIU 48.82
- Support Level
- NUW $13.71
- ACIU $2.05
- Resistance Level
- NUW $13.85
- ACIU $2.25
- Average True Range (ATR)
- NUW 0.10
- ACIU 0.17
- MACD
- NUW 0.01
- ACIU -0.02
- Stochastic Oscillator
- NUW 35.88
- ACIU 19.57
About NUW Nuveen AMT-Free Municipal Value Fund
Nuveen AMT-Free Municipal Value Fund is a diversified closed-end management investment company. Its investment objective is to provide current income exempt from regular federal income tax by investing in a portfolio of municipal obligations. The fund predominantly invests in long-term municipal bonds, corporate bonds, short-term municipal bonds, and other assets.
About ACIU AC Immune SA
AC Immune SA is a clinical-stage biopharmaceutical company that focuses on neurodegenerative diseases. The company uses its proprietary technology platforms to discover, design, and develop novel proprietary small molecules, antibodies, and vaccines for the prevention, diagnosis, and treatment of neurodegenerative diseases associated with protein misfolding. The Company has one segment. The Company currently focuses mostly of its resources on discovering and developing therapeutic and diagnostic products targeting misfolded proteins. The company's pipeline consists of ACI-24.060, Crenezumab, ACI-35.030, Semorinemab, ACI-7104.056, and others.